What is the step‑by‑step anesthetic management plan for a patient undergoing surgical excision of a left atrial myxoma, including pre‑operative assessment, induction, maintenance, cardiopulmonary bypass management, and postoperative care?

Anesthetic Management of Left Atrial Myxoma Surgical Excision

Left atrial myxoma resection requires meticulous hemodynamic management to prevent tumor embolization and cardiovascular collapse, with immediate availability of cardiopulmonary bypass and careful avoidance of tumor manipulation until bypass is established.

Pre-operative Assessment

Cardiac Evaluation

• Obtain transthoracic echocardiography to confirm tumor size, location, attachment site, mobility, and degree of mitral valve obstruction 1, 2, 3.
• Assess left ventricular function and evaluate for any concomitant valvular disease that may require simultaneous correction 4.
• Perform baseline ECG to identify pre-existing arrhythmias or conduction abnormalities, as myxomas can cause bradycardia and rhythm disturbances 5.
• Consider coronary angiography in patients >40 years old or with cardiac risk factors, as concomitant coronary artery bypass may be needed 2.

Neurological Assessment

• Screen for history of embolic events, stroke, or transient ischemic attacks, as embolic complications occur frequently with atrial myxomas 1, 5.
• If neurological symptoms are present, obtain brain imaging to identify cerebral aneurysms or prior embolic infarcts, which may alter blood pressure management targets 6.
• Document baseline neurological examination for post-operative comparison 6.

Risk Stratification

• This is high-risk cardiac surgery requiring cardiopulmonary bypass 1, 2.
• Continue beta-blockers if patient is already taking them for any indication 4, 7.
• Continue statins if patient is already on them 4, 7.
• Do not delay surgery for cardiac optimization, as myxomas carry high risk of sudden death from valve obstruction or catastrophic embolization 2.

Pre-operative Preparation

Medication Management

• Continue beta-blockers throughout the perioperative period if already prescribed 4, 7.
• Continue statins if already prescribed 4, 7.
• Hold antiplatelet agents only if bleeding risk outweighs thrombotic risk, though this is rarely applicable in myxoma surgery 4.
• Consider ACE inhibitors or ARBs if patient has heart failure with LVEF <40% 4, 7.

Monitoring Setup

• Establish large-bore peripheral IV access (minimum two 16-gauge or larger) before induction 4.
• Place arterial line for continuous blood pressure monitoring before induction 4.
• Defer central venous catheter and pulmonary artery catheter placement until after induction to avoid dislodging tumor fragments during line insertion 6.
• Prepare transesophageal echocardiography (TEE) probe for immediate use after intubation 4, 6.

Induction of Anesthesia

Critical Principles

• Maintain hemodynamic stability and avoid tachycardia, which increases risk of tumor embolization and mitral valve obstruction 6.
• Minimize cardiac manipulation and avoid vigorous bag-mask ventilation that could dislodge tumor fragments 6.
• Have cardiopulmonary bypass circuit primed and surgeon scrubbed before induction 1, 2.

Induction Technique

• Use etomidate (0.2-0.3 mg/kg) or low-dose propofol (1-1.5 mg/kg) with high-dose opioid (fentanyl 10-20 mcg/kg or sufentanil 2-5 mcg/kg) for hemodynamic stability 4.
• Administer non-vagolytic neuromuscular blocker (rocuronium 0.6-1.2 mg/kg or vecuronium 0.1-0.15 mg/kg) to avoid tachycardia associated with pancuronium 4.
• Perform gentle direct laryngoscopy and intubation, avoiding hypertensive response that could dislodge tumor 6.

Immediate Post-Intubation

• Insert TEE probe to visualize tumor position, mobility, and mitral valve function 4, 6.
• Place central venous catheter via internal jugular approach under ultrasound guidance 4.
• Consider brain tissue oxygen monitoring (PbtO2) if patient has known cerebral aneurysms 6.

Maintenance of Anesthesia

Anesthetic Agents

• Use volatile anesthetic agents (sevoflurane or isoflurane 0.5-1.5 MAC) for myocardial protection during ischemia-reperfusion, combined with opioid infusion 4.
• Alternatively, total intravenous anesthesia with propofol (50-150 mcg/kg/min) and opioid infusion is acceptable 4.
• Administer benzodiazepines (midazolam 0.05-0.1 mg/kg) for amnesia 4.

Hemodynamic Goals

• Maintain heart rate 60-80 bpm to minimize tumor movement and optimize cardiac output 4.
• Target mean arterial pressure 65-80 mmHg, or higher (80-90 mmHg) if cerebral aneurysms are present 6.
• Avoid hypertension (>140 mmHg systolic) that could cause tumor embolization 6.
• Treat hypotension with phenylephrine or norepinephrine rather than increasing heart rate 4.

Pre-Bypass Management

• Minimize cardiac manipulation before bypass to prevent tumor fragmentation and embolization 1, 2.
• Maintain normovolemia with restrictive fluid strategy 4.
• Have vasopressors and inotropes immediately available 4.

Cardiopulmonary Bypass Management

Anticoagulation

• Administer heparin 300-400 units/kg to achieve activated clotting time >480 seconds before cannulation 4.
• Avoid central venous cannulation through the tumor-bearing atrium; use bicaval cannulation for right atrial myxomas 2.

Bypass Conduct

• Administer low-concentration volatile anesthetic (0.5-1.0 MAC) via oxygenator during bypass for amnesia and vasodilation 4.
• Maintain mean arterial pressure 50-70 mmHg during bypass 4.
• Use moderate hypothermia (28-32°C) for cerebral protection given embolic risk 6.
• Maintain normothermia (36-37°C) during rewarming to reduce cardiac complications 4.

Surgical Excision Phase

• Surgeon must excise tumor with wide margin of atrial septum to prevent recurrence 1, 2.
• TEE confirms complete tumor removal and assesses for residual fragments 6.
• Inspect all cardiac chambers via biatrial approach to exclude additional tumors 2.

Separation from Cardiopulmonary Bypass

Preparation

• Ensure adequate rewarming to core temperature >36°C 4.
• Verify adequate de-airing of cardiac chambers with TEE 6.
• Assess ventricular function and valvular competence with TEE 4, 6.

Weaning Strategy

• Gradually reduce bypass flow while monitoring hemodynamics and ventricular filling 4.
• Initiate inotropic support (epinephrine 0.02-0.05 mcg/kg/min or milrinone 0.375-0.75 mcg/kg/min) if ventricular dysfunction is present 4.
• Maintain heart rate 80-100 bpm during separation to optimize cardiac output 4.

Post-Bypass Anticoagulation Reversal

• Administer protamine 1 mg per 100 units of heparin given, infused slowly over 10-15 minutes to avoid hypotension 4.

Post-operative Management

Immediate Post-operative Care

• Transport patient to intensive care unit intubated and sedated for initial stabilization 4.
• Continue hemodynamic monitoring with arterial line and central venous catheter 4.
• Perform immediate post-operative ECG and chest radiograph 4.

Extubation Strategy

• Plan early extubation (within 4-8 hours) in uncomplicated cases using fast-track cardiac anesthesia protocols 4, 6.
• Extubate when patient is hemodynamically stable, normothermic, awake, and has adequate respiratory mechanics 4.
• Perform immediate neurological assessment after extubation to detect embolic complications 6.

Hemodynamic Management

• Target heart rate 60-80 bpm with beta-blockers if needed 4.
• Maintain mean arterial pressure 65-80 mmHg (or 80-90 mmHg if cerebral aneurysms present) 6.
• Continue inotropic support as needed, weaning gradually over 12-24 hours 4.

Monitoring and Surveillance

• Obtain transthoracic echocardiography before discharge to confirm complete tumor removal and assess cardiac function 2.
• Monitor for arrhythmias, particularly atrial fibrillation, which is common after atrial surgery 5.
• Perform neurological examination every 4 hours for first 24 hours to detect delayed embolic events 6.

Long-term Follow-up

• Schedule echocardiographic surveillance at 6 months, 1 year, and annually thereafter to detect rare tumor recurrence 2, 6.
• Recurrence rate is <5% for sporadic myxomas but higher for familial cases 2.
• If cerebral aneurysms were identified, arrange neurosurgical follow-up with serial imaging 6.

Critical Pitfalls to Avoid

• Never insert central lines or pulmonary artery catheters before induction in patients with mobile atrial tumors, as wire passage could fragment the tumor 6.
• Never perform vigorous cardiac manipulation or TEE probe insertion before establishing bypass, as this risks catastrophic embolization 1, 6.
• Avoid tachycardia throughout the perioperative period, as increased cardiac motion promotes tumor embolization 6.
• Do not delay surgery for extensive preoperative testing, as sudden death from valve obstruction or embolization can occur 2.
• Never assume complete tumor removal without TEE confirmation and four-chamber inspection, as incomplete excision leads to recurrence 2.